



---

Title:

**Clinical Comparison of 4 Daily Disposable Soft Contact Lenses**

Protocol Number: CLE383-C004 / NCT03349632

Sponsor Name and Address: Alcon Research, Ltd.  
6201 South Freeway  
Fort Worth, Texas 76134-2099

Test Product(s): Daily Disposable T2 Soft Contact Lenses (DD T2 Contact Lenses)

Investigator Agreement: I have read the clinical study described herein, recognize its confidentiality, and agree to conduct the described trial in compliance with Good Clinical Practice (GCP), the ethical principles contained within the Declaration of Helsinki, this protocol, and all applicable regulatory requirements. Additionally, I will comply with all procedures for data recording and reporting, will permit monitoring, auditing, and inspection of my research center, and will retain all records until notified by the Sponsor.

Principal Investigator:

---

Signature


Date

Name:

Address:



**1 PROTOCOL SYNOPSIS**

Trial Sponsor	Alcon Research, Ltd. 6201 South Freeway Fort Worth, Texas 76134-2099
Name of Test Product	DD T2
Name of Control Products	<ul style="list-style-type: none"> <li>• ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ Technology (Oasys 1-Day)</li> <li>• CooperVision® MyDay® (MyDay)</li> <li>• 1-Day ACUVUE® MOIST (Moist)</li> </ul>
Title of Trial	Clinical Comparison of 4 Daily Disposable Soft Contact Lenses
Protocol Number	CLE383-C004
Number of Sites	~3
Country	US
Planned Duration of Exposure	~20 days total duration <ul style="list-style-type: none"> <li>• Test Product: 8 days (-1/+2 days)</li> <li>• Control Products: 8 days (-1/+2 days)</li> </ul>
Number of Subjects	Target to complete: 60 (20 per each parallel group) Planned to enroll: ~66 (~22 per each parallel group)
Study Population	Volunteer subjects aged 18 or over who are soft daily disposable contact lens wearers (excluding current Oasys 1-Day, MyDay, and Moist wearers), have at least 3 months of contact lens wearing experience, and who wear their habitual lenses at least 5 days per week and at least 8 hours per day.
Objectives	The primary objective of this study is to evaluate the overall performance of DD T2 lenses when compared to Oasys 1-Day, MyDay, and Moist lenses.
Endpoints	Primary Effectiveness <ul style="list-style-type: none"> <li>• Overall quality of vision</li> </ul> 

	<p>Safety</p> <ul style="list-style-type: none"> <li>• AEs</li> <li>• Biomicroscopy findings</li> <li>• Device deficiencies</li> </ul>				
<p>Assessments</p>	<p>Effectiveness</p> <ul style="list-style-type: none"> <li>- VA (Snellen distance)</li> </ul> <div data-bbox="573 415 1442 682" style="background-color: black; height: 127px; width: 100%;"></div> <ul style="list-style-type: none"> <li>- Overall quality of vision</li> </ul> <div data-bbox="573 714 1442 1058" style="background-color: black; height: 164px; width: 100%;"></div> <p>Safety</p> <ul style="list-style-type: none"> <li>- AEs</li> <li>- Biomicroscopy</li> <li>- Device deficiencies</li> </ul>				
<p>Study Design</p>	<table border="1" style="width: 100%;"> <tr> <td data-bbox="513 1236 924 1457"> <input checked="" type="checkbox"/> Prospective  <input type="checkbox"/> Single group  <input checked="" type="checkbox"/> Parallel group  <input checked="" type="checkbox"/> Crossover  <input type="checkbox"/> Other                 </td><td data-bbox="924 1236 1451 1457"> <input type="checkbox"/> Single-masked (trial subject)  <input type="checkbox"/> Single-masked (Investigator)  <input checked="" type="checkbox"/> Double-masked  <input type="checkbox"/> Open-label  <input type="checkbox"/> Other                 </td></tr> <tr> <td data-bbox="513 1457 924 1572"> <input type="checkbox"/> Contralateral  <input checked="" type="checkbox"/> Bilateral  <input type="checkbox"/> Monocular lens wear                 </td><td data-bbox="924 1457 1451 1572"> <input checked="" type="checkbox"/> Randomized                 </td></tr> </table> <p>This is a 3-arm, parallel, crossover group study design. In each arm, the test lens will be evaluated compared to one of 3 chosen control lenses. Approximately 22 subjects will be randomized to 1 of the 6 lens sequences consisting of 2 crossover sequences of test vs. control within each of the 3 parallel groups. Subjects will wear the assigned study Lens 1 bilaterally for approximately 1 week before crossing over into the assigned study Lens 2 bilaterally for approximately 1 week. This same design will be scheduled for each of the 3 arms.</p>	<input checked="" type="checkbox"/> Prospective <input type="checkbox"/> Single group <input checked="" type="checkbox"/> Parallel group <input checked="" type="checkbox"/> Crossover <input type="checkbox"/> Other	<input type="checkbox"/> Single-masked (trial subject) <input type="checkbox"/> Single-masked (Investigator) <input checked="" type="checkbox"/> Double-masked <input type="checkbox"/> Open-label <input type="checkbox"/> Other	<input type="checkbox"/> Contralateral <input checked="" type="checkbox"/> Bilateral <input type="checkbox"/> Monocular lens wear	<input checked="" type="checkbox"/> Randomized
<input checked="" type="checkbox"/> Prospective <input type="checkbox"/> Single group <input checked="" type="checkbox"/> Parallel group <input checked="" type="checkbox"/> Crossover <input type="checkbox"/> Other	<input type="checkbox"/> Single-masked (trial subject) <input type="checkbox"/> Single-masked (Investigator) <input checked="" type="checkbox"/> Double-masked <input type="checkbox"/> Open-label <input type="checkbox"/> Other				
<input type="checkbox"/> Contralateral <input checked="" type="checkbox"/> Bilateral <input type="checkbox"/> Monocular lens wear	<input checked="" type="checkbox"/> Randomized				

	<b>Study Visits:</b> <ol style="list-style-type: none"> <li>1. Baseline/Dispense Lens 1</li> <li>2. Day 8 (-1/+2 days) follow-up Lens 1/Dispense Lens 2</li> <li>3. Day 8 (-1/+2 days) follow-up Lens 2/Exit</li> </ol>	
Test Product Details	Primary component/material	██████
	Product Name	DD T2
	LID Number	LID 006841
	Manufacturer	Alcon
	Other	The lenses will be available in -1.00 D to -6.00 D (0.25 D steps)
Control Product 1 Details	Primary component/material	senofilcon A
	Product Name	Oasys 1-Day
	LID Number	LID 009601
	Manufacturer	Johnson and Johnson Vision
	Other	The lenses will be available in -1.00 D to -6.00 D (0.25D steps)
Control Product 2 Details	Primary component/material	stenfilcon A
	Product Name	MyDay
	LID Number	LID 009602
	Manufacturer	CooperVision
	Other	The lenses will be available in -1.00 D to -6.00 D (0.25 D steps)
Control Product 3 Details	Primary component/material	etafilcon A
	Product Name	Moist
	LID Number	LID 009603
	Manufacturer	Johnson and Johnson Vision
	Other	The lenses will be available in -1.00 D to -6.00 D (0.25 D steps)
Inclusion Criteria	<ol style="list-style-type: none"> <li>1. Subject must be at least 18 years of age.</li> <li>2. Subject must be able to understand and must sign an ICF that has been approved by an IRB.</li> <li>3. Successful wear of daily disposable spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months.</li> <li>4. Manifest cylinder <math>\leq 0.75</math> D in each eye.</li> <li>5. BCVA 20/25 or better in each eye.</li> <li>6. Subject must be willing to stop wearing their habitual contact lenses for the duration of study participation.</li> </ol>	
Exclusion Criteria	<ol style="list-style-type: none"> <li>1. Any anterior segment infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the Investigator.</li> <li>2. Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the Investigator.</li> <li>3. History of refractive surgery or plan to have refractive surgery during the study or irregular cornea in either eye.</li> </ol>	

	<ol style="list-style-type: none"> <li>4. Ocular or intraocular surgery (excluding placement of punctal plugs) within the previous 12 months or planned during the study.</li> <li>5. Biomicroscopy findings at screening that are moderate (Grade 3) or higher and/or corneal vascularization that is mild (Grade 2) or higher.</li> <li>6. Current or history of pathologically dry eye in either eye that, in the opinion of the Investigator, would preclude contact lens wear.</li> <li>7. Current or history of herpetic keratitis in either eye.</li> <li>8. Eye injury in either eye within 12 weeks immediately prior to enrollment for this trial.</li> <li>9. Current or history of intolerance, hypersensitivity, or allergy to any component of the study products.</li> <li>10. Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment.</li> <li>11. Any use of topical ocular medications and artificial tear or rewetting drops that would require instillation during contact lens wear.</li> <li>12. The Investigator, his/her staff, family members of the Investigator, family members of the Investigator's staff, or individuals living in the households of the aforementioned persons may not participate in the study.</li> <li>13. Participation of the subject in a clinical trial within the previous 30 days or currently enrolled in any clinical trial.</li> <li>14. Currently wearing Oasys 1-Day, MyDay, or Moist contact lenses.</li> <li>15. Habitually wearing monovision or multifocal lenses during the last 3 months.</li> </ol>
Associated Materials	Lubrication/re-wetting drops will not be permitted.

**Table 1–1 Schedule of Study Procedures and Assessments**

<b>Procedure/ Assessment</b>	<b>Visit 1, Day 1:</b> Baseline/ Dispense Lens 1	<b>Visit 2, Week 1:</b> Day 8 of lens wear (-1/+2 days) Follow-up Lens 1/ Dispense Lens 2	<b>Visit 3, Week 2:</b> Day 8 of lens wear (-1/+2 days) Follow-up Lens 2/ Exit	<b>Unscheduled Visit</b>
Informed Consent	✓	-	-	-
Demographics	✓	-	-	-
Medical History	✓	-	-	-
Concomitant Medications	✓	(✓)	(✓)	(✓)
Inclusion/ Exclusion	✓	-	-	-
Habitual lens (brand, power)*	✓	-	-	-

Procedure/ Assessment	Visit 1, Day 1: Baseline/ Dispense Lens 1	Visit 2, Week 1: Day 8 of lens wear (-1/+2 days) Follow-up Lens 1/ Dispense Lens 2	Visit 3, Week 2: Day 8 of lens wear (-1/+2 days) Follow-up Lens 2/ Exit	Unscheduled Visit
VA w/ habitual correction (OD, OS, Snellen distance)*	✓	-	✓	(✓)
Biomicroscopy	✓	✓	✓	✓
Dispense study lenses	✓	✓	-	-
VA w/ study lenses (OD, OS, Snellen distance)	✓	✓	✓	(✓)
Subjective rating with study lenses:				
• [REDACTED]				
• [REDACTED]				
• [REDACTED]				
• [REDACTED]				
• overall quality of vision		✓ (Follow-up Lens 1)	✓	✓
• [REDACTED]				
• [REDACTED]				

Procedure/ Assessment	Visit 1, Day 1: Baseline/ Dispense Lens 1	Visit 2, Week 1: Day 8 of lens wear (-1/+2 days) Follow-up Lens 1/ Dispense Lens 2	Visit 3, Week 2: Day 8 of lens wear (-1/+2 days) Follow-up Lens 2/ Exit	Unscheduled Visit
AEs	✓	✓	✓	✓
Device deficiencies	✓	✓	✓	✓
Exit Form	(✓)	(✓)	(✓)	(✓)

(✓) assessment performed as necessary, eg, decrease of VA by 2 lines or more with investigational product (IP)

\* Source only

† Comments, optional

## 1.1 Abbreviations

**Table 1–2 Table of Abbreviations**

Abbreviation	Definition
ADE	Adverse device effect
ASADE	Anticipated serious adverse device effect
AE	Adverse event
BCVA	Best corrected visual acuity
CFR	Code of Federal Regulations
D	Diopter
DD	Daily Disposable
eCRF	Electronic case report form
EDC	Electronic data capture
FDA	US Food and Drug Administration
GCP	Good Clinical Practice
IB	Investigator's brochure
ICF	Informed consent form
IP	Investigational product
IRB	Institutional review board
ISO	International Organization for Standardization
mm	Millimeter
MOP	Manual of procedures
N/A	Not applicable
OD	Right eye
OS	Left eye
OU	Both eyes
SAE	Serious adverse event
SADE	Serious adverse device effect
US	United States
USADE	Unanticipated serious adverse device effect
VA	Visual acuity

## 2 TABLE OF CONTENTS

1	PROTOCOL SYNOPSIS .....	2
	Clinical Comparison of 4 Daily Disposable Soft Contact Lenses .....	2
1.1	Abbreviations .....	7
2	TABLE OF CONTENTS.....	8
	List of Tables.....	10
	List of Figures .....	10
3	INTRODUCTION .....	11
3.1	Study Rationale and Purpose.....	11
3.2	Trial Objective .....	11
3.3	Risks and Benefits .....	11
3.4	Subject Population.....	12
3.5	Outline of Study .....	12
4	TREATMENTS ADMINISTERED.....	12
4.1	Identity of Study Treatments .....	13
4.2	Accountability Procedures.....	14
5	STUDY PROCEDURES AND ASSESSMENTS .....	15
5.1	Visits and Examinations .....	15
5.1.1	Visit 1 (Day 1) – Baseline/Dispense Lens 1 .....	15
5.1.2	Visit 2, Week 1 [Day 8 (-1/+2 Days)] – Follow-Up Lens 1/Dispense Lens 2 .....	17
5.1.3	Visit 3, Week 2 [Day 8 (-1/+2 Days)] – Follow-Up Lens 2/Exit.....	19
5.2	Unscheduled Visits .....	21
5.3	Discontinued Subjects .....	21
5.4	Clinical Study Termination.....	22
6	ANALYSIS PLAN .....	22
6.1	Subject Evaluability.....	23
6.2	Analysis Data Sets.....	23
6.2.1	Safety Analysis Set .....	23
6.3	Demographic and Baseline Characteristics .....	23
6.4	Effectiveness Analyses .....	23
6.4.1	Primary Effectiveness.....	23

6.4.1.1	Statistical Hypotheses .....	23
6.4.1.2	Analysis Methods .....	23
6.4.2	Secondary Effectiveness.....	24
		24
		24
		24
6.5	Subgroup Analyses .....	25
6.6	Handling of Missing Data .....	25
6.7	Multiplicity.....	25
6.8	Safety Analysis .....	25
6.9	Interim Analyses .....	26
		26
7	ADVERSE EVENTS AND DEVICE DEFICIENCIES .....	26
7.1	General Information .....	28
7.2	Monitoring for Adverse Events .....	31
7.3	Procedures for Recording and Reporting .....	31
7.4	Return product analysis .....	33
7.5	Follow-Up of Subjects with Adverse Events.....	33
7.6	Pregnancy in the Clinical Study .....	34
8	CONFIDENTIALITY, BIAS, AND MASKING.....	34
8.1	Subject Confidentiality and Methods Used to Minimize Bias .....	34
8.2	Unmasking of the Study Treatment.....	35
9	DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS .....	35
9.1	Completion of Source Documents and Case Report Forms.....	35
9.2	Data Review and Clarifications.....	36
9.3	Regulatory Documentation and Records Retention .....	36
10	ETHICS AND COMPLIANCE.....	36
10.1	Compliance.....	37
10.2	Institutional Review Board (IRB) .....	37
11	PROTOCOL AMENDMENT HISTORY .....	38
12	REFERENCES .....	38
12.1	References applicable for all clinical trials .....	38
12.1.1	US references applicable for clinical trials.....	38

12.2

References for this clinical trial.....

38

**List of Tables**

Table 1–1

Schedule of Study Procedures and Assessments .....

5

Table 1–2

Table of Abbreviations .....

7

Table 4–1

Description of Test and Control Products .....

13

Table 7-1

Terms and Definitions .....

26

**List of Figures**

Figure 7–1

Categorization of All AEs .....

28

Figure 7-2

Categorization of All Serious Adverse Events.....

29

### **3 INTRODUCTION**

#### **3.1 Study Rationale and Purpose**

The purpose of this study is to obtain on-eye performance data to inform contact lens product development and to further evaluate product performance in the intended population. The primary endpoint was selected to fulfil the primary objective of the study. Procedures for measurement of these endpoints were selected based on common practice for these assessments. The design of this study is justified based upon preclinical and clinical testing, as described within the Investigator's Brochure. Oasys 1-Day, MyDay, and Moist contact lenses were chosen as the control products because these lenses have the same wear modality. The new contact lens in development is intended for the optical correction of refractive myopia in persons with non-diseased eyes.

There are no immediate plans to submit the results of this study for publication; however, the results may be offered for publication if they are of scientific interest, or if the results relate to a product that is subsequently approved or cleared for marketing.

#### **3.2 Trial Objective**

The primary objective of this study is to evaluate the overall performance of DD T2 lenses when compared to Oasys 1-Day, MyDay, and Moist lenses.

#### **3.3 Risks and Benefits**

Contact lenses may offer improved peripheral vision and the convenience of not wearing spectacles. Material properties and design characteristics of the contact lens in development are features consistent with successful contact lens wear.

Based upon non-clinical testing and/or documented rationale for applicability of test results to the IP, the new contact lens in development is assessed to be non-toxic and biocompatible for on-eye use.

The new contact lens in development and the 3 control contact lenses are not intended for use with a cleaning/disinfecting solution, and the biocompatibility with lens care solutions and any associated clinical effects are unknown.

A summary of the known potential risks and benefits associated with the new contact lens in development can be found in the Investigator's Brochure. There may also be unknown risks with the use of the new contact lens. Risks are minimized by compliance with the eligibility criteria and study procedures, and through close supervision by a licensed clinician during

exposure to the study lenses. The potential harms associated with on-eye exposure to the new lens materials include toxicity response, blurred vision and ocular discomfort. In general, the risks with the new contact lens in development are anticipated to be similar to other marketed daily disposable soft contact lenses.

The site personnel will educate subjects on proper hygiene and lens handling, and compliance with the use of contact lenses according to the protocol. Subjects should be instructed not to wear contact lenses while sleeping or swimming. The site personnel will also advise the subjects to remove contact lenses and return for prompt follow-up of symptoms, such as ocular discomfort, foreign body sensation, excessive tearing, vision changes, or hyperemia.

### 3.4 Subject Population

The study population includes approximately 66 volunteer subjects to be enrolled at approximately 3 sites, with approximately 22 subjects enrolled per site. The study population will consist of subjects with normal eyes (other than the need for optical correction for myopia), and who are adapted, existing wearers of daily disposable soft contact lenses in both eyes.

Subjects must be screened according to the full list of inclusion/exclusion criteria in Section 1 of this protocol. Rescreening of subjects is not allowed in this study.

### 3.5 Outline of Study

This will be a multi-site, prospective, randomized, parallel crossover, double-masked study comparing 4 contact lenses. The expected duration of subject participation in the study is approximately 20 days, with 3 scheduled visits. The study is expected to be completed in approximately 7 weeks.

## 4 TREATMENTS ADMINISTERED

This is a 3-arm, parallel, crossover group study design. In each arm, the test lens will be evaluated compared to 1 of 3 chosen control lenses. Subjects will be randomized to 1 of the 6 lens sequences, as described below:

Sequence 1: DD T2 → Oasys 1-Day

Sequence 2: Oasys 1-Day → DD T2

Sequence 3: DD T2 → MyDay

Sequence 4: MyDay → DD T2

Sequence 5: DD T2 → Moist

Sequence 6: Moist → DD T2

## 4.1 Identity of Study Treatments

**Table 4-1 Description of Test and Control Products**

	Test Lens	Control 1 Lens	Control 2 Lens	Control 3 Lens
LID Number	LID 006841	LID 009601	LID 009602	LID 009603
Lens	DD T2	Oasys 1-Day	MyDay	Moist
Material	██████	senofilcon A	stenfilcon A	etafilcon A
Water Content	██████	38%	54%	58%
Base Curve (mm)	8.3	8.5	8.4	8.5
Diameter (mm)	14.2	14.3	14.2	14.2
Rx powers to be available in this study	-1.00 to -6.00 D (0.25 D steps)	-1.00 to -6.00 D (0.25 steps)	-1.00 to -6.00 D (0.25 D steps)	-1.00 to -6.00 D (0.25 D steps)
Packaging, Labeling, and Supply	<ul style="list-style-type: none"> <li>Blister foil pack</li> <li>Foil label includes at a minimum: <ul style="list-style-type: none"> <li>material name and/or identifier</li> <li>base curve</li> <li>diameter</li> <li>manufacturing protocol number</li> <li>packing solution</li> <li>power</li> <li>lot number</li> <li>expiration date</li> <li>content statement</li> <li>investigational device statement</li> <li>Sponsor information</li> <li>country of origin</li> </ul> </li> <li>Provided in boxes of 12 lenses per</li> </ul>	<ul style="list-style-type: none"> <li>Blister foil pack</li> <li>Foil label includes at a minimum: <ul style="list-style-type: none"> <li>material name and/or identifier</li> <li>base curve</li> <li>diameter</li> <li>packing solution</li> <li>power</li> <li>lot number</li> <li>expiration date</li> <li>content statement</li> <li>investigational device statement</li> <li>Sponsor information</li> <li>country of origin</li> </ul> </li> <li>Provided in boxes of 12 lenses per power per box,</li> </ul>	<ul style="list-style-type: none"> <li>Blister foil pack</li> <li>Foil label includes at a minimum: <ul style="list-style-type: none"> <li>material name and/or identifier</li> <li>base curve</li> <li>diameter</li> <li>packing solution</li> <li>power</li> <li>lot number</li> <li>expiration date</li> <li>content statement</li> <li>investigational device statement</li> <li>Sponsor information</li> <li>country of origin</li> </ul> </li> <li>Provided in boxes of 12 lenses per power per box, identified with</li> </ul>	<ul style="list-style-type: none"> <li>Blister foil pack</li> <li>Foil label includes at a minimum: <ul style="list-style-type: none"> <li>material name and/or identifier</li> <li>base curve</li> <li>diameter</li> <li>packing solution</li> <li>power</li> <li>lot number</li> <li>expiration date</li> <li>content statement</li> <li>investigational device statement</li> <li>Sponsor information</li> <li>country of origin</li> </ul> </li> <li>Provided in boxes of 12 lenses per power per box, identified with</li> </ul>

	power per box, identified with the following at a minimum: <ul style="list-style-type: none"> <li>- a color coded label stating the protocol number</li> <li>- material identifier</li> <li>- power</li> <li>- an investigational use only statement</li> <li>- tracking number</li> <li>• Lenses should be stored at room temperature.</li> </ul>	identified with the following at a minimum: <ul style="list-style-type: none"> <li>- a color coded label stating the protocol number</li> <li>- material name or identifier</li> <li>- power</li> <li>- an investigational use only statement</li> <li>- tracking number</li> <li>• Lenses should be stored at room temperature.</li> </ul>	the following at a minimum: <ul style="list-style-type: none"> <li>- a color coded label stating the protocol number</li> <li>- material name or identifier</li> <li>- power</li> <li>- an investigational use only statement</li> <li>- tracking number</li> <li>• Lenses should be stored at room temperature.</li> </ul>	the following at a minimum: <ul style="list-style-type: none"> <li>- a color coded label stating the protocol number</li> <li>- material name or identifier</li> <li>- power</li> <li>- an investigational use only statement</li> <li>- tracking number</li> <li>• Lenses should be stored at room temperature.</li> </ul>
Usage	<ul style="list-style-type: none"> <li>• Wear:             <ul style="list-style-type: none"> <li>○ Daily wear</li> <li>○ Bilateral, parallel crossover group</li> </ul> </li> <li>• Replacement period: Daily Disposable</li> <li>• Exposure: At least 8 hours per day, at least 5 days per week over the study treatment duration.</li> <li>• Lens Care: N/A</li> </ul>			

## 4.2 Accountability Procedures

Upon receipt of the study lenses, the Investigator or delegate will conduct an inventory. Designated study staff will provide the study lenses to the subjects in accordance with their randomization schedule. Throughout the study, the Investigator or delegate must maintain records of study treatment dispensation and collection for each subject. This record must be made available to the study monitor for the purposes of verifying the accounting of clinical supplies. Any discrepancies and/or deficiencies between the observed disposition and the written account must be recorded along with an explanation.

It is the Investigator's responsibility to ensure that:




- All study products are accounted for and not used in any unauthorized manner

- All used foils and unused supplies are returned by each subject
- All unused products are available for return to the Study Sponsor, as directed
- Any study lenses associated with a device deficiency or with any product-related adverse event [ie, ADE or SADE] are returned to the Study Sponsor for investigation. Refer to Section 7.3 of this protocol for additional information on the reporting of device deficiencies and AEs and the return of study products associated with these events.

## 5 STUDY PROCEDURES AND ASSESSMENTS

### 5.1 Visits and Examinations

#### 5.1.1 Visit 1 (Day 1) – Baseline/Dispense Lens 1

1	Explain the purpose and nature of the study, and have the subject read, sign, and date the IRB-approved informed consent document. Additionally, have the individual obtaining consent from the subject and a witness, if applicable, sign and date the informed consent document. Provide a photocopy of the signed document to the subject and place the original signed document in the subject's chart. After signing the ICF, a subject will be assigned a subject number by the EDC system. A signed informed consent document defines the point of enrollment.
2	Obtain demographic information and medical history, including information on all medications used within the past 30 days. Include herbal therapies, vitamins, and all over-the-counter as well as prescription medications.
3	
4	Perform Snellen VA with habitual correction. <ul style="list-style-type: none"><li>• OD, OS, distance only, contact lenses</li><li>• Over-refraction (only needed if VA is reduced)</li></ul> Record habitual lens information (brand, power).
5	
6	

7	<p>Perform slit-lamp biomicroscopy (without contact lenses) to evaluate the following:</p> <ul style="list-style-type: none"> <li>• Limbal hyperemia</li> <li>• Bulbar hyperemia</li> <li>• Corneal staining</li> <li>• Conjunctival staining</li> <li>• Palpebral conjunctival observations</li> <li>• Corneal epithelial edema</li> <li>• Corneal stromal edema</li> <li>• Corneal vascularization</li> <li>• Conjunctival compression/indentation</li> <li>• Chemosis</li> <li>• Corneal infiltrates</li> <li>• Other findings</li> </ul>
8	<p>[REDACTED]</p> <p>[REDACTED]</p>
9	<p>Review inclusion/exclusion criteria to determine if the subject qualifies to be randomized into the study. If subject qualifies, request randomization. If subject does not qualify, exit the subject from the study as a screen failure.</p>
10	<p>Based upon the randomized treatment sequence assignment, have the subject insert the appropriate study lenses.</p> <ul style="list-style-type: none"> <li>• <i>Keep all lidding foils of lenses used during lens fit process for study lens accountability.</i></li> <li>• <i>Follow procedures to maintain masking.</i></li> </ul>
11	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
12	<p>Evaluate the study lenses by performing the following:</p> <ul style="list-style-type: none"> <li>• Snellen VA with study lenses (OD and OS, at distance)*</li> <li>• Over-refraction if necessary to determine the best contact lens-corrected VA and final study lens power(s)</li> </ul> <p><i>*VA w/study lenses must be 20/40 OU or better for subject to leave the office</i></p>

13	
14	Assess and record any AEs and device deficiencies reported or observed during the study visit. <i>Note: AEs and device deficiencies must be recorded for all enrolled subjects from the time of signature of informed consent including those that screen fail.</i>
15	Dispense study lenses (Lens 1). Provide the subject with written and verbal instructions on lens wear.
16	Schedule Visit 2 to take place on Day 8 (-1/+2 days) of lens wear (Lens 1).
17	<i>Note: If for some reason a subject is unable to wear a study lens <b>for the duration of this visit window</b>, instruct the subject to return to the site for an Unscheduled Visit as well as lens removal on site, if possible. The subject should then be scheduled to return to the clinic for Visit 2 (if possible) or exited from the study.</i>

### 5.1.2 Visit 2, Week 1 [Day 8 (-1/+2 Days)] – Follow-Up Lens 1/Dispense Lens 2

1	Obtain information on any changes in medical health and/or the use of concomitant medications.
2	Record any device deficiencies or AEs including those associated with changes in concomitant medication dosing, which are observed or reported since the previous visit(s).
3	Review subject compliance with lens wear and adjunct product usage.
4	Administer Subjective Questionnaire to assess: <ul style="list-style-type: none"> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• Subjective overall quality of vision, OU</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> </ul>

5	Evaluate the study lenses by performing the following: <ul style="list-style-type: none"> <li>• Snellen VA with study lenses (OD and OS, at distance)</li> </ul>
6	
7	Perform slit-lamp biomicroscopy (without contact lenses) to evaluate the following: <ul style="list-style-type: none"> <li>• Limbal hyperemia</li> <li>• Bulbar hyperemia</li> <li>• Corneal staining</li> <li>• Conjunctival staining</li> <li>• Palpebral conjunctival observations</li> <li>• Corneal epithelial edema</li> <li>• Corneal stromal edema</li> <li>• Corneal vascularization</li> <li>• Conjunctival compression/indentation</li> <li>• Chemosis</li> <li>• Corneal infiltrates</li> <li>• Other findings</li> </ul>
8	Based upon the randomized treatment sequence assignment, have the subject insert the Lens 2 study lenses to be evaluated. <i>Note: Keep all lidding foils of lenses used during lens fit process for study lens accountability.</i>
9	
10	Evaluate the study lenses by performing the following: <ul style="list-style-type: none"> <li>• Snellen VA with study lenses (OD and OS, at distance)*</li> <li>• Over-refraction if necessary to determine the best contact lens-corrected VA and final study lens power(s)</li> </ul> <p><i>*VA w/study lenses must be 20/40 OU or better for subject to leave the office</i></p>

11	
12	<p>Assess and record any AEs and device deficiencies <u>reported or observed during the study visit</u>.</p> <p><i>Note: AEs and device deficiencies must be recorded for all enrolled subjects from the time of signature of informed consent regardless of their enrollment status (screen failure or randomized).</i></p>
13	Dispense study lenses (Lens 2). Provide the subject with written and verbal instructions on lens wear.
14	Schedule Visit 3 to take place Day 8 (-1/+2 days) of lens wear (Lens 2).
15	<p><i>Note: If for some reason a subject is unable to wear a study lens <b>for the duration of this visit window</b>, instruct the subject to return to the site for an <b>Unscheduled Visit</b> as well as lens removal on site, if possible. The subject should then be scheduled to return to the clinic for Visit 3 (if possible) or exited from the study.</i></p>

### 5.1.3 Visit 3, Week 2 [Day 8 (-1/+2 Days)] – Follow-Up Lens 2/Exit

1	Obtain information on any changes in medical health and/or the use of concomitant medications.
2	Record any device deficiencies or AEs including those associated with changes in concomitant medication dosing, which are observed or reported since the previous visit(s).
3	Review subject compliance with lens wear and adjunct product usage.
4	<p>Administer Subjective Questionnaire to assess:</p> <ul style="list-style-type: none"> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• Subjective overall quality of vision, OU</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> </ul>

5	Evaluate the study lenses by performing the following: <ul style="list-style-type: none"> <li>• Snellen VA with study lenses (OD and OS, at distance)</li> </ul>
6	
7	Perform slit-lamp biomicroscopy (without contact lenses) to evaluate the following: <ul style="list-style-type: none"> <li>• Limbal hyperemia</li> <li>• Bulbar hyperemia</li> <li>• Corneal staining</li> <li>• Conjunctival staining</li> <li>• Palpebral conjunctival observations</li> <li>• Corneal epithelial edema</li> <li>• Corneal stromal edema</li> <li>• Corneal vascularization</li> <li>• Conjunctival compression/indentation</li> <li>• Chemosis</li> <li>• Corneal infiltrates</li> <li>• Other findings</li> </ul>
8	Assess and record any AEs and device deficiencies <u>reported or observed during the study visit</u> . Note: AEs and device deficiencies must be recorded for all enrolled subjects from the time of signature of informed consent regardless of their enrollment status (screen failure or randomized).
9	Perform Snellen VA with habitual correction. <ul style="list-style-type: none"> <li>• OD, OS, distance only, contact lenses</li> </ul> <i>Note: If this VA with habitual correction shows a decrease of 2 lines or more versus Visit 1 baseline VA with habitual correction, then BCVA with MR is required to confirm a potential loss in VA for AE reporting requirements (see Section 7).</i>
10	Exit the subject from the study.

## 5.2 Unscheduled Visits

Any visit that occurs between regularly scheduled visits is an Unscheduled Visit. If a subject requires an Unscheduled Visit, he/she must be advised to return to the office wearing the study lenses, if at all possible (unless he/she is experiencing a sign or symptom [as indicated in Section 3.3 Risks and Benefits]). During all unscheduled visits, the Investigator must conduct the following procedures:

- Collect AE and device deficiency information
- Assess and record changes in medical condition or concomitant medication
- Assess and record VAs
- Perform biomicroscopy (assessments with or without lenses, as possible)

In addition, all procedures for Visit 3 (Follow-up Lens 2/Exit) should be completed (as possible). The Investigator may perform additional procedures for proper diagnosis and treatment of the subject. The Investigator must document this information in the subject's case history source documents.

If during an Unscheduled Visit the subject is discontinuing the study lenses or discontinuing from the study, the Investigator must conduct Exit procedures according to Table 1-1: Schedule of Study Procedures and Assessments, as possible.

## 5.3 Discontinued Subjects

Discontinued subjects are those who withdraw or are withdrawn from the study after signing the informed consent, including screen failures. Subjects may discontinue from the study at any time for any reason. Subjects may also be discontinued from the study at any time if, in the opinion of the Investigator, their continued participation poses a risk to their health.

Discontinued subjects will not be replaced (ie, their subject numbers will not be re-assigned/re-used).

Should a subject exhibit any clinically relevant signs, symptoms, or other clinical observations that possibly could be associated with suspected sensitivity or intolerance to one of the study treatments, the Investigator must document those observations on an AE Form.

Any subject who exits early from the study (excluding screen failures) must undergo all procedures outlined at Visit 3, as applicable.

The Investigator must document the reason for study or treatment discontinuation in the subject's case history source documents.

To ensure the safety of all subjects who discontinue early, Investigators must assess each subject and, if necessary, advise them of any therapies and/or medical procedures that may be needed to maintain their health.

## 5.4 Clinical Study Termination

The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause.

If the clinical study is prematurely terminated or suspended by the Study Sponsor:

- The Study Sponsor must:
  - Immediately notify the Investigator(s) and subsequently provide instructions for study termination.
  - Inform the Investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable.
- The Investigator must:
  - Promptly notify the IRB of the termination or suspension and of the reasons.
  - Provide subjects with recommendations for post-study treatment options as needed.

The Investigator may terminate a site's participation in the study for reasonable cause.

## 6 ANALYSIS PLAN

Continuous variables will be summarized using the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarized with counts and percentages from each category. Any deviations to this analysis plan will be updated during the course of the study as part of a protocol amendment or will be detailed in the clinical study report.

## **6.1 Subject Evaluability**

The final subject evaluability will be determined prior to breaking the code for masked treatment sequence assignment and locking the database, based on the Deviations and Evaluability Plan.

## **6.2 Analysis Data Sets**

### **6.2.1 Safety Analysis Set**

Safety analyses will be conducted using the safety analysis set on a treatment-emergent basis. As such, the safety analysis set will include all subjects/eyes exposed to any study lenses evaluated in this study. For treatment-emergent safety analyses, subjects/eyes will be categorized under the actual study lenses exposed.

## **6.3 Demographic and Baseline Characteristics**

Demographic information (age, sex, ethnicity, race) will be summarized on the Safety Analysis Set Baseline data pertaining to habitual lens [REDACTED] [REDACTED] will be summarized on the Safety Analysis Set as well.

## **6.4 Effectiveness Analyses**

This study defines one primary endpoint [REDACTED] Data for DD T2 will be summarized according to the crossover control worn per each parallel group. The Safety Analysis Set will serve as the primary set for all effectiveness analyses.

### **6.4.1 Primary Effectiveness**

The primary objective of this study is to evaluate the overall performance of DD T2 lenses when compared to Oasys 1-Day, MyDay and 1-Day Acuvue Moist. The primary endpoint is the subjective rating on overall quality of vision, collected binocularly on a scale of 1 (Poor) to 10 (Excellent).

#### **6.4.1.1 Statistical Hypotheses**




No inferences are to be made on the primary effectiveness endpoint/s, therefore no hypotheses are formulated.

#### **6.4.1.2 Analysis Methods**

Descriptive statistics will be provided.

## 6.4.2 Secondary Effectiveness

No secondary objective or endpoint is defined for this study.



## 6.5 Subgroup Analyses

It is not expected that demographic or baseline characteristics will have an impact on the study results in this study. No subgroup analyses are planned.

## 6.6 Handling of Missing Data

All data obtained in evaluable subjects/eyes will be included in the analysis. No imputation for missing values will be carried out for the primary analysis.

## 6.7 Multiplicity

No multiplicity adjustment needs to be considered for the effectiveness endpoints since no formal hypothesis testing will be conducted.

## 6.8 Safety Analysis

The safety endpoints for this study are AEs, biomicroscopy findings, and device deficiencies. Data for DD T2 will be summarized according to the crossover control worn per each parallel group.

Descriptive summaries (counts and percentages) for ocular and nonocular AEs will be presented by Medical Dictionary for Regulatory Activities Preferred Terms. AEs leading to study discontinuation, significant non-serious AEs, and SAEs will be identified. Individual subject listings will be provided, as necessary.

Individual subject listings will be provided for AEs that occur after signing informed consent but prior to exposure to study lenses.

Each biomicroscopy parameter will be tabulated by its grade. For each biomicroscopy parameter, counts and percentages of eyes that experience an increase of  $\geq 2$  grades from Baseline (Visit 1) to any subsequent visit will be presented. A supportive listing will be generated which will include all biomicroscopy data from all visits for these eyes experiencing the increase.

Two listings (prior to exposure of study lenses and treatment-emergent) of device deficiencies, as recorded on the Device Deficiency Form, will be provided. Additionally, each device deficiency category will be tabulated.

No inferential testing will be done for safety analysis.

## 6.9 Interim Analyses

There are no plans to conduct an interim analysis and no criteria by which the study would be terminated early based upon statistical determination.

## 7 ADVERSE EVENTS AND DEVICE DEFICIENCIES

**Table 7-1** Terms and Definitions

Adverse event (AE)	Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device (test product). <i>Note: For subjects, this definition includes events related to the test product, the control product, or the procedures involved. For users or other persons, this definition is restricted to events related to the test product.</i>
Adverse device effect (ADE)	AE related to the use of an investigational medical device (test product) or control product. <i>Note: This definition includes AEs resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation; any malfunction; and use error or intentional misuse of the test product or control product.</i>
Anticipated serious adverse device effect (ASADE)	Serious ADE which by its nature, incidence, severity or outcome has been identified in the risk management file.
Device deficiency	Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance. <i>Note: This definition includes malfunctions, use errors, and inadequate labeling.</i>
Malfunction	Failure of a medical device to meet its performance specifications or otherwise perform as intended. Performance specifications include all claims made in the labeling of the device. The intended performance of the device refers to the intended use for which the

	device is labeled or marketed.
Non-serious adverse event	AE that does not meet the criteria for an SAE.
Serious adverse event (SAE)	<p>AE that led to any of the following:</p> <ul style="list-style-type: none"> <li>• Death.</li> <li>• A serious deterioration in the health of the subject that either resulted in: <ul style="list-style-type: none"> <li>a) a life-threatening illness or injury. <i>Note: Life-threatening means that the individual was at immediate risk of death from the event as it occurred, ie, it does not include an event which hypothetically might have caused death had it occurred in a more severe form.</i></li> <li>b) any potentially sight-threatening event or permanent impairment to a body structure or a body function.</li> <li>c) in-patient hospitalization or prolonged hospitalization. <i>Note: Planned hospitalization for a pre-existing condition, without serious deterioration in health, is not considered an SAE. In general, hospitalization signifies that the individual remained at the hospital or emergency ward for observation and/or treatment (usually involving an overnight stay) that would not have been appropriate in the physician's office or an out-patient setting. Complications that occur during hospitalization are adverse events. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether "hospitalization" occurred, the event should be considered serious.</i></li> <li>d) a medical or surgical intervention to prevent a) or b).</li> <li>e) any indirect harm as a consequence of incorrect diagnostic test results when used within manufacturer's instructions for use.</li> </ul> </li> <li>• Fetal distress, fetal death, or a congenital abnormality or birth defect.</li> </ul> <p><i>Refer to Section 7.1 for additional SAEs.</i></p>
Serious adverse device effect (SADE)	ADE that has resulted in any of the consequences characteristic of an SAE.
Significant non-	A significant non-serious AE is a symptomatic, device-related,

serious adverse event	non-sight threatening AE that warrants discontinuation of any contact lens wear for greater than or equal to 2 weeks. <i>Refer to Section 7.1 for additional Significant Non-Serious AEs.</i>
Unanticipated serious adverse device effect (USADE)	Serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the risk management file.
Use Error	Act or omission of an act that results in a different medical device response than intended by manufacturer or expected by user. <i>Note: This definition includes slips, lapses, and mistakes. An unexpected physiological response of the subject does not in itself constitute a use error.</i>

## 7.1 General Information

An AE is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the investigational medical device (*test article*).

**Figure 7–1**                      **Categorization of All AEs**





Figure 7-2

## Categorization of All Serious Adverse Events

***Serious Adverse Events***

In addition to reporting all AEs (serious and non-serious) meeting the definitions, the Investigator must report any occurrence of the following as an SAE:

- An ocular infection including a presumed infectious ulcer with any of the following characteristics:
  - Central or paracentral location
  - Penetration of Bowman's membrane
  - Infiltrates > 2 mm diameter
  - Iritis
  - Increase in intraocular pressure
  - Culture positive for microorganisms
  - Increasing size or severity at subsequent visits
- Any central or paracentral corneal event (such as neovascularization) that results in permanent opacification
- Hypopyon
- Hyphema

- Neovascularization within the central 6 mm of the cornea
- Permanent vision loss as defined by loss of 2 or more lines of BCVA from enrollment visit that fails to resolve
- Uveitis (anterior, intermediate, or posterior)
- Corneal abrasion affecting  $\geq 50\%$  of corneal surface area

***Significant Non-Serious Adverse Events***

A significant non-serious AE is a symptomatic, device-related, non-sight threatening AE that warrants discontinuation of any contact lens wear for greater than or equal to 2 weeks. In addition, the Investigator must report any occurrence of the following as a Significant Non-Serious AE:

- Peripheral non-progressive non-infectious ulcers
- All symptomatic corneal infiltrative events
- Corneal staining score greater than or equal to Grade 3 (Refer to MOP for grading scales) [Grading scale is based on ISO 11980:2012 unless specified differently in MOP]
- Temporary vision loss as defined by loss of 2 or more lines of BCVA from enrollment visit that persists for 2 or more weeks
- Neovascularization score greater than or equal to Grade 2

*The above events are based upon the categories provided in the ISO 11980:2012 and the US FDA Premarket Notification (510(k)) Guidance Document for Daily Wear Contact Lenses and Contact Lens Care Products.*

***Device Deficiencies***

A device deficiency is inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance. A device deficiency may or may not be associated with patient harm (ie, ADE or SADE); however, not all ADEs or SADEs are due to a device deficiency. The Investigator should determine the applicable category listed in the Device Deficiency eCRF for the identified or suspect device deficiency and report any patient harm separately. Examples of device deficiencies include the following:

- Failure to meet product specifications (eg, incorrect lens power/diameter/base curve/color)

- Lens cloudy
- Lens surface/edge defect
- Torn lens during handling/in pack
- Packaging deficit (eg, mislabeled product, tampered seal, leaking bottle/container)
- Suspect product contamination
- Lack of performance

## 7.2 Monitoring for Adverse Events

At each visit, after the subject has had the opportunity to spontaneously mention any problems, the Investigator should inquire about AEs by asking the standard questions:

- “Have you had any health problems since your last study visit?”
- “Have there been any changes in the medicines you take since your last study visit?”

Additionally, changes in *any protocol-specific parameters and/or questionnaires* evaluated during the study are to be reviewed by the Investigator. Any untoward (unfavorable and unintended) change in *a protocol-specific parameter or questionnaire response* that is clinically relevant, in the opinion of the Investigator, is to be reported as an AE. These clinically relevant changes will be reported regardless of causality.

## 7.3 Procedures for Recording and Reporting

AEs are collected from the time of informed consent. Any pre-existing medical conditions or signs/symptoms present in a subject prior to the start of the study (ie, before informed consent is signed) are not considered AEs in the study and should be recorded in the Medical History section of the eCRF.

In addition, temporary lens awareness or visual changes during the fitting process are not considered AEs if the Investigator assesses that the symptom(s) can reasonably resolve within the anticipated adaptation period.

- ADEs or SAEs are documented on the *Serious Adverse Event and Adverse Device Effect* eCRF within 24 hours of the Investigator’s or site’s awareness.
- Device deficiencies are documented on the *Device Deficiency* eCRF within 24 hours of the Investigator’s or site’s awareness.

- A printed copy of the completed *Serious Adverse Event and Adverse Device Effect* and/or *Device Deficiency* eCRF must be included with product returns.
- Additional relevant information after initial reporting must be entered into the eCRF as soon as the data become available.
- Document any changes to concomitant medications on the appropriate eCRFs.
- Document all relevant information from Discharge Summary, Autopsy Report,
- Certificate of Death, etc, if applicable, in narrative section of the *Serious Adverse Event and Adverse Device Effect* eCRF.

*Note:* Should the EDC system become non-operational, the site must complete the appropriate paper *Serious Adverse Event and Adverse Device Effect* and/or *Device Deficiency* Form. The completed form is emailed to the Study Sponsor at [REDACTED] according to the timelines outlined above; however, the reported information must be entered into the EDC system once it becomes operational.

Any AEs and device deficiencies for non-study marketed devices/products will be considered and processed as spontaneous (following the postmarket vigilance procedures) and should be communicated to the device's/product's manufacturer as per local requirements.

Study Sponsor representatives may be contacted for any protocol related question and their contact information is provided in the MOP that accompanies this protocol.

Further, depending upon the nature of the AE or device deficiency being reported, the Study Sponsor may request copies of applicable portions of the subject's medical records. The Investigator must also report all AEs and device deficiencies that could have led to a SADE according to the requirements of regulatory authorities or IRB/IEC.

### **Intensity and Causality Assessments**

Where appropriate, the Investigator must assess the intensity (severity) of the AE based upon medical judgment with consideration of any subjective symptom(s), as defined below:

#### ***Intensity (Severity)***

Mild            An AE is mild if the subject is aware of but can easily tolerate the sign or symptom.

Moderate      An AE is moderate if the sign or symptom results in discomfort significant enough to cause interference with the subject's usual activities.

**Severe** An AE is severe if the sign or symptom is incapacitating and results in the subject's inability to work or engage in their usual activities.

For every AE in the study, the Investigator must assess the causality (Related or Not Related to the medical device or study procedure). An assessment of causality will also be performed by Study Sponsor utilizing the same definitions, as shown below:

### ***Causality***

**Related** An AE classified as related may be either definitely related or possibly related where a direct cause and effect relationship with the medical device or study procedure has not been demonstrated, but there is a reasonable possibility that the AE was caused by the medical device or study procedure.

**Not Related** An AE classified as not related may either be definitely unrelated or simply unlikely to be related (ie, there are other more likely causes for the AE).

The Study Sponsor will assess the AEs and may upgrade the Investigator's assessment of seriousness and/or causality. The Study Sponsor will notify the Investigator of any AEs that are upgraded from non-serious to serious or from unrelated to related.

## **7.4 Return product analysis**

Alcon products associated with device deficiencies and/or product related AEs should be returned and must include the Complaint # which will be provided by Study Sponsor after the case is entered in the Study Sponsor's Global Product Complaint Management System. These products should be returned to the Sponsor at the end of the study, unless instructed otherwise by the Sponsor.

## **7.5 Follow-Up of Subjects with Adverse Events**

The Investigator is responsible for adequate and safe medical care of subjects during the study and for ensuring that appropriate medical care and relevant follow-up procedures are maintained after the study.

The Investigator should provide the Study Sponsor with any new safety information (which includes new AEs and changes to previously reported AEs) that may affect the safety evaluation of the device. For AEs that are unresolved/ ongoing at time of subject exit from study, any additional information received at follow-up should be documented in the eCRFs up to study completion (ie, database lock).

Any additional data received up to 1 month after subject discontinuation or exit must be documented and available upon the Study Sponsor's request. All complaints received after this time period will be considered and processed as spontaneous and should be communicated to the medical device's manufacturer as per local requirements.

The Investigator should also report complaints on non-Alcon products directly to the manufacturer as per the manufacturer's instructions or local regulatory requirements.

## 7.6 Pregnancy in the Clinical Study

Women of childbearing potential or women who are pregnant at the time of study entry are not excluded from participation. Pregnancy should be included in the Medical History section of the eCRF when a pregnant woman enters the study or if a woman becomes pregnant during the study. Pregnancy is not reportable as an AE; however, complications may be reportable and will be decided on a case-by-case basis.

## 8 CONFIDENTIALITY, BIAS, AND MASKING

### 8.1 Subject Confidentiality and Methods Used to Minimize Bias

The Investigator must ensure that the subject's anonymity is maintained throughout the course of the study. In particular, the Investigator must keep an enrollment log with confidential identifying information that corresponds to the subject numbers and initials of each study participant. At the end of the clinical study, the Sponsor will collect a copy of the enrollment log without any identifying subject information. All documents submitted to the Sponsor will identify the subjects exclusively by number and demographic information. No other personally identifying information should be transmitted to the Sponsor.

This study is double-masked with subjects randomized to use both DD T2 and the assigned control product (in a randomized sequence) for the duration of the treatment period. The Investigator and Sponsor personnel (other than site monitors, lead clinical site manager, person responsible for generating the randomization schedule, and unmasked clinical data managers) involved in reporting, obtaining, and/or reviewing the clinical evaluations will be masked to the identity of the contact lens being administered. This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked. Masked study personnel must avoid seeking information that may compromise masking. Unmasked study personnel must not disseminate information that is potentially unmasking to any masked personnel. The **masked** and **unmasked** site personnel must coordinate all study activities as necessary to protect masking and minimize bias during the trial.

## **8.2 Unmasking of the Study Treatment**

Masked information on the identity of the assigned medical device should not be disclosed during the study. If the treatment code needs to be broken in the interest of subject safety, the Investigator is encouraged to contact an appropriate Study Sponsor representative prior to unmasking the information if there is sufficient time. Dependent upon the individual circumstances (ie, medical emergency), the code may be broken prior to contact with the Study Sponsor. The Study Sponsor must be informed of all cases in which the code was broken and of the circumstances involved. Additionally, the Study Sponsor may be required to unmask the information in order to fulfill expedited regulatory reporting requirements.

## **9 DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS**

### **9.1 Completion of Source Documents and Case Report Forms**

The nature and location of all source documents will be identified to ensure that original data required to complete the eCRFs exist and are accessible for verification by the site monitor, and all discrepancies shall be appropriately documented via the query resolution process. Study monitors are appointed by the Study Sponsor and are independent of study site staff. If electronic records are maintained, the method of verification must be determined in advance of starting the study.

At a minimum, source documents should include the following information for each subject:

- Subject identification (name, sex, race/ethnicity)
- Documentation of subject eligibility
- Date of informed consent
- Dates of visits
- Documentation that protocol specific procedures were performed
- Results of study parameters, as required by the protocol
- IP accountability records
- Documentation of AEs and other safety parameters (if applicable)
- Records regarding medical histories and the use of concomitant therapies prior to and during the study
- Date of study completion and reason for early discontinuation, if applicable

It is required that the author of an entry in the source documents be identifiable. Direct access to source documentation (medical records) must be allowed for the purpose of verifying that the data recorded on the eCRF are consistent with the original source data.

Only designated individuals may complete the eCRFs. The eCRFs will be submitted at regular intervals following the clinical study visit schedule. It is expected that all data reported will have corresponding entries in the source documents. The Principal Investigator is responsible for reviewing and certifying that the eCRFs are accurate and complete. The only subject identifiers recorded on the eCRFs will be subject number, and subject demographic information.

## **9.2 Data Review and Clarifications**

Upon completion of the eCRFs, a targeted review of the eCRF data to the subject's source data will be completed by the site monitor to ensure completeness and accuracy. Additional data clarifications and/or additions may be needed as a result of the data cleaning process. Data clarifications are documented and are part of each subject's eCRFs.

## **9.3 Regulatory Documentation and Records Retention**

The Investigator is required to maintain up-to-date, complete regulatory documentation as indicated by the Sponsor and the Investigator's files will be reviewed as part of the ongoing study monitoring. Financial disclosure is not subject to regulatory inspection and should be kept separately.

Additionally, the Investigator must keep study records and source documents until the Sponsor provides written approval for their destruction. If the Investigator retires, relocates, or for any other reason withdraws from responsibility of keeping the study records, the Sponsor must be notified and suitable arrangements made for retention of study records and source documents needed to comply with national and international regulations (generally 2 years after discontinuing clinical development or after the last marketing approval).

## **10 ETHICS AND COMPLIANCE**

This trial will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the referenced directives, regulations, guidelines, and/or standards.

## 10.1 Compliance

The Investigator must ensure that all personnel involved in the conduct of the study are qualified to perform their assigned responsibilities through relevant education, training, and experience. The Investigator and all clinical study staff must conduct the clinical study in compliance with the protocol. Deviations from this protocol, regulatory requirements and/or GCP must be recorded and reported to the Sponsor prior to database lock. If needed, corrective and preventive action should be identified, implemented, and documented within the study records.

## 10.2 Institutional Review Board (IRB)

This trial requires IRB approval prior to initiation. This protocol, subject informed consent, and subsequent amendments will be reviewed and approved by an IRB.

Before clinical study initiation, this protocol, the ICF (and assent form, if applicable), any other written information given to subjects, and any advertisements planned for subject recruitment must be approved by an IRB. The Investigator must provide documentation of the IRB approval to the Study Sponsor. The approval must be dated and must identify the applicable protocol, amendments (if any), ICF, assent form (if any), all applicable recruiting materials, written information for subject, and subject compensation programs. The IRB must be provided with a copy of the Investigator's Brochure, any periodic safety updates, and all other information as required by local regulation and/or the IRB. At the end of the study, the Investigator must notify the IRB about the study's completion. The IRB also must be notified if the study is terminated prematurely. Finally, the Investigator must report to the IRB on the progress of the study at intervals stipulated by the IRB.

Voluntary informed consent must be obtained from every subject (and/or legal representative, as applicable) prior to the initiation of any screening or other study-related procedures. The Investigator must have a defined process for obtaining consent. Specifically, the Investigator, or delegate, must explain the clinical study to each potential subject and the subject must indicate voluntary consent by signing and dating the approved informed consent form. The subject must be provided an opportunity to ask questions of the Investigator, and if required by local regulation, other qualified personnel. The Investigator must provide the subject with a copy of the consent form written in a language the subject understands. The consent document must meet all applicable local laws and provide subjects with information regarding the purpose, procedures, requirements, and restrictions of the study, along with any known risks and potential benefits associated with the IP, the available compensation, and the established provisions for maintaining confidentiality of personal, protected health information. Subjects will be told about the voluntary nature of participation in the study and

must be provided with contact information for the appropriate individuals should questions or concerns arise during the study. The subject also must be told that their records may be accessed by appropriate authorities and Sponsor-designated personnel. The Investigator must keep the original, signed copy of the consent and must provide a duplicate copy to each subject according to local regulations. Following this study, the subject will return to their eye care professional for their routine eye care and contact lenses.

## 11 PROTOCOL AMENDMENT HISTORY

Version	Brief Description and Rationale
1	Initial Version of this document

## 12 REFERENCES

### 12.1 References applicable for all clinical trials

- ISO 11980:2012 Ophthalmic optics - Contact lenses and contact lens care products - Guidance for clinical investigations
- ISO 14155:2011 Clinical investigation of medical devices for human subjects - Good clinical practice

#### 12.1.1 US references applicable for clinical trials

- 21 CFR Part 11 - Electronic Records; Electronic Signatures
- 21 CFR Part 50 - Protection of Human Subjects
- 21 CFR Part 56 - Institutional Review Boards
- 21 CFR Part 812 - Investigational Device Exemptions
- 21 CFR Part 54 - Financial Disclosure by Clinical Investigators
- The California Bill of Rights.

### 12.2 References for this clinical trial

Not applicable.

Date/Time (mm/dd/yyyy GMT):	Signed by:	Justification:
10/31/2017 19:36:06	<div></div>	<div></div>
10/31/2017 20:07:40	<div></div>	<div></div>
11/02/2017 13:25:44	<div></div>	<div></div>